TRAX vs FTRE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
TRAX · First Tracks Biotherapeutics$47.90 ▲ 5.44%
FTRE · Fortrea Holdings$21.96 ▲ 7.33%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- TRAX +152.1%
- FTRE +143.7%
Head to head
| Metric | TRAX | FTRE |
|---|---|---|
| Price | $47.90 | $21.96 |
| Change today | ▲ 5.44% | ▲ 7.33% |
| Market cap | $2.01B | $2.12B |
| Return, 3 months | 0.0% | +15.6% |
| Return, year to date | – | +27.3% |
| Return, 1 year | – | +95.2% |
| P/E (TTM) | – | – |
| P/B | 13.3 | 4.0 |
| P/E percentile vs own 5y | 7th | 13th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | -1.4% |
| Net profit growth (YoY) | +21.4% | +103.8% |
| Gross margin | – | 20.0% |
| Operating margin | – | 1.7% |
| Net margin | – | -2.6% |
| Return on equity | – | -12.3% |
| Analyst target vs. price | +54.9% | +16.4% |
| Analyst buy share | 100% | 70% |
| RSI (14) | 65 | 51 |
| 30-day volatility | 74.8% | 64.9% |
| Max drawdown, 1 year | -39.7% | -51.8% |
| Trend read | Strong uptrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- FTRE is the largest of the group by market value.
- FTRE has been the calmest stock over the last 30 days.